2 results
Approved WMOCompleted
The primary objectives of this study are:- To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT proBNP from baseline after 12 weeks of treatment in patients with HFpEF.- To demonstrate that LCZ696…
Approved WMOWill not start
To compare the antiproteinuric effects of sacubitril/valsartan (ARNI) and valsartan (ARB).